Asthma is a serious clinical manifestation. Every year many people died all over the world about this manifestation. In the United States alone, there are an estimated 18.7 million people with asthma, accounting for 17 million ambulatory care visits and nearly 500,000 hospitalizations.
iSonea applies a novel approach to get some objective data on asthma – in essence, it “listens” to patients breath and analyzes the sounds for signs of wheezing, rhonchi, and other abnormalities. The Wheezometer, shown here, is a noninvasive device that measures the “wheeze rate” simply by analyzing the sounds of a patient breathing. And while its a separate device now, the company plans to change that – they recently discussed plans to shift to a smartphone-based platform.
They have recently announced the launch of a study – the Wheezometer Correlation Study – that aims to directly correlate the wheeze rate measured by the device with spirometry data, exam findings, and symptom severity. This study represents one of the critical steps a novel device must take before entering widespread use.
n the acute management of asthma and other pulmonary diseases with a reactive airways component, history and exam are crucial. As subjective measures, they are prone to issues like inter-observer variability, unclear histories, and so on. Additionally, children often won’t even be able to provide a history. iSonea’s WheezoMeter analyzes 30 seconds of breath sounds using a variety signal processing algorithms to detect, quantify and objectively document the presence of wheeze and its extent. The wheeze rate is the proportion of the respiratory cycle duration occupied by wheezing. They demonstrated the device at HIMSS this year.